The primary aim of the trial is to determine whether the new combination improves the time patients live without their disease getting worse and, for a portion of the study, also extends overall survival compared with standard care.

Participants are randomly assigned to receive either the experimental medicines or the usual therapy, with treatment given in repeated cycles of intravenous infusions and oral tablets over several months. Throughout the study, doctors monitor tumor size using imaging scans evaluated by the criteria called RECIST 1.1, record how long the disease stays stable (progression free survival), note the length of life from start of treatment (overall survival), and assess how many patients experience tumor shrinkage (objective response rate). Safety is evaluated by tracking side effects, vital signs, laboratory tests and heart rhythm recordings.

The purpose of the study is to see how well these approaches shrink or control the tumors. Participants are randomly assigned to one of the treatment groups and receive a series of infusion visits over several weeks, with regular check‑ups to look at tumor size and overall health.

During the study, doctors will measure the objective response rate, which means the proportion of patients whose tumors get smaller or disappear, and will also watch for any side effects or changes in blood tests. The schedule includes clinic visits for the infusions, imaging scans to view the tumors, and laboratory tests to ensure safety.

The main goal of the trial is to learn how safe the medicine is and how well patients can tolerate increasing doses. Participants will receive the drug in a series of treatment cycles that last about four weeks each, with the amount of medicine gradually increased in early groups to find the highest dose that can be given without unacceptable side effects.

During the study, patients will have regular check‑ups, blood tests, and scans to watch for any side effects and to see how the cancer responds. Any problems that arise will be recorded and managed by the medical team, and the study will continue until the predetermined number of treatment cycles is completed or if a participant chooses to stop early.

The treatment involves the intravenous administration of SGN-ALPV, meaning the medicine is delivered directly into a vein through a needle or tube. Participants in the study will receive the drug in different amounts to help researchers determine the highest dose that can be given safely without causing too many side effects. During the study, medical professionals will monitor how the body reacts to the medication and how much of the drug remains in the bloodstream over time.

The study is divided into different phases. In the first phase, the study will test different doses of ONA-255 to find the lowest dose that has a biological effect and the highest dose that people can tolerate without serious side effects. In the next phase, the study will focus on finding the best dose to use for future studies in people with hormone receptor-positive, HER2-negative breast cancer and possibly in people with metastatic gastric or gastroesophageal junction cancer. In the final phase, the study will look at how many people respond to treatment with ONA-255 at the recommended dose. Throughout the study, doctors will monitor participants closely with physical examinations, blood tests, and imaging scans to check how the cancer is responding and to watch for any side effects.

The study will also collect blood samples to measure how the body processes ONA-255 and how long it stays in the body. Tissue samples from the cancer may be collected to study markers like FGFR4, HER2, and genetic changes such as ESR1, PIK3CA, TP53, and RB1 mutations to better understand how the treatment works. Some participants may also have their response measured using RECIST criteria, which is a standard way of measuring tumor size changes. The study may use placebo in some cases. Doctors will track how long the treatment works, how long people live without their cancer getting worse, and overall survival.

Patients in this study will receive zanidatamab on its own, without combining it with other cancer treatments. The medicine will be given regularly over a treatment period that can last up to 60 weeks. The doctors will check how the tumors respond to the treatment by doing regular scans and tests. Some patients in the study may have breast cancer or cancers of the stomach and food pipe area, and they may have received a specific type of HER2-targeted therapy before, which is a treatment that works against the HER2 protein. For other types of solid tumors, patients should not have had this type of treatment before.

During the study, doctors will monitor patients carefully to see if the treatment is working and to watch for any side effects. This includes checking heart function, blood tests to see how the liver and kidneys are working, and measuring the size of the tumors. Patients will also be asked about symptoms they experience using questionnaires. The study will look at how many patients see their tumors shrink, how long the treatment keeps working, and how long patients live. Blood samples will be taken to measure the amount of medicine in the body and to check if the body makes any reaction against the medicine.

The main purpose of this study is to find out if adding FRUZAQLA to Lonsurf helps people live longer compared to taking Lonsurf alone. The study will also look at how long patients live without their cancer getting worse, how well the tumors respond to treatment, and how the treatments affect quality of life. The safety of the treatments will be carefully monitored, and any side effects will be recorded. Patients will be assigned randomly to one of the two treatment groups, meaning that neither the patient nor the doctor chooses which treatment is given.

During the study, patients will take their assigned medicines for up to six months, and their health will be regularly checked through medical examinations and scans to see how the cancer is responding. Quality of life will be measured using questionnaires that ask about daily activities and symptoms. The study is expected to start enrolling patients in early 2026 and continue until early 2029. Patients will need to provide tumor tissue samples for testing and agree to participate in additional biological studies as part of the research.

The main purpose of this research is to determine if adding Zolbetuximab to the standard treatment improves survival in patients whose tumors test positive for CLDN18.2 and who have not previously received any CLDN18.2-targeted therapy. The treatment involves receiving medications through intravenous infusion, which means the medicine is given directly into a vein.

During the study, participants will receive treatment for up to 24 months. The medications will be given at regular intervals, with Zolbetuximab administered at specific doses calculated based on body surface area. Throughout the treatment period, doctors will monitor the participants’ health status and track how the disease responds to the treatment combination.

Participants may receive a combination of the study drug pumitamig (also referred to as BNT327) and chemotherapy. The chemotherapy medications involved include oxaliplatin, fluorouracil, and capecitabine, sometimes used alongside calcium folinate. In the first part of the study, two different doses of pumitamig are tested to see which one works best. In the second part, the more effective dose is compared to a standard treatment consisting of nivolumab and chemotherapy.

The study is conducted in stages. Initially, the goal is to determine which dose of the new medicine is most effective at controlling tumor growth while minimizing side effects. Following this, the selected dose is evaluated to see if it can extend progression-free survival, which is the length of time a patient lives with the disease without it getting worse, and overall survival, which is the total length of time a patient remains alive.

The study is divided into different parts. In the first parts, called Part A, Part B, and Part C, researchers will test different doses of the drug to find out which dose is safe and works best. They will carefully watch for any side effects and see how the body processes the drug. In Part D, the study will focus specifically on people with pancreatic adenocarcinoma and will look more closely at whether the drug helps shrink tumors or stop them from growing. During the study, participants will receive the study drug and will have regular check-ups to monitor their health and see how the cancer is responding to treatment.

Throughout all parts of the study, doctors will measure how much of the drug is in the blood, watch for any unwanted effects, and check if the cancer gets better, stays the same, or gets worse. They will also test whether the body develops an immune response to the drug over time. The study will track how long any positive effects last and whether people need to stop treatment or change their dose because of side effects. All participants must have already tried standard treatments that are normally used for their type of cancer, and those treatments must not have worked well enough or must no longer be available as an option.

The purpose of this study is to evaluate how well the combination of zanidatamab with pembrolizumab and chemotherapy works in treating patients who have not previously received treatment for their advanced cancer. The study will look at whether this treatment combination can help control the disease and how long patients remain without their cancer getting worse.

During the study, patients will receive the study medications according to a specific treatment schedule that may continue for up to 104 weeks. Throughout this time, doctors will regularly monitor the patients through various examinations and tests to assess how the cancer responds to treatment and to watch for any side effects. The study will measure several outcomes including how many patients respond to the treatment, how long the treatment keeps the cancer under control, and the overall survival of patients. Safety will be carefully monitored by tracking any unwanted effects that occur during treatment, and quality of life will be assessed using questionnaires.

The study involves people whose tumors test negative for a protein called HER2 but positive for two other proteins called CLDN18.2 and PD-L1. During the study, participants will receive either zolbetuximab or a placebo along with pembrolizumab and chemotherapy through intravenous infusions. Some chemotherapy medications will be given as tablets to take by mouth.

Researchers will track how long participants live, whether their cancer grows or spreads, and how their tumors respond to treatment. They will also monitor participants for any side effects from the treatment combination. The study will check blood samples to measure drug levels and test for the body’s immune response to the medications.

The treatment involves a combination of several cancer medications administered through intravenous infusion. These medications include fluorouracil, docetaxel, oxaliplatin, carboplatin, paclitaxel, and folinic acid. These drugs work together to kill cancer cells or stop them from growing. The medications will be given in specific sequences and combinations over several weeks.

The study will examine how well patients respond to this treatment by measuring how long they remain free from cancer progression. The treatment plan includes giving these medications before surgery, which is different from traditional approaches where some treatments are given after surgery. This approach aims to potentially improve outcomes for patients with this type of cancer.

The purpose of this research is to evaluate how safe these medications are and how well patients tolerate them when given before and after surgery. The study will also look at how effective the treatments are at fighting the cancer before surgery is performed. During the study, patients will receive the study medications, undergo surgery to remove the cancer, and then continue with additional treatment after surgery.

This is an open-label study, which means both doctors and patients will know which medication is being given. The study will include multiple treatment groups testing different combinations of these medications. Patients will be assigned to specific treatment groups based on certain characteristics of their cancer, including whether their cancer cells have specific markers called CLDN18.2 or HER2.

The purpose of the study is to evaluate the safety and effectiveness of this combination treatment. Participants will receive these medications through an intravenous injection, which means the drugs are delivered directly into the bloodstream through a vein. The study will compare this new combination to a standard treatment known as FOLFOX, which includes Oxaliplatin, Fluorouracil, and Leucovorin, along with Budigalimab. The trial aims to determine if the new combination can improve outcomes for patients, such as slowing the progression of the disease or increasing survival time.

Participants in the study will receive treatment over a period of up to nine months. During this time, they will be closely monitored by healthcare professionals to assess how well the treatment is working and to check for any side effects. The study will help researchers understand if the new combination of drugs can be a better option for treating these types of cancer compared to existing treatments. This research is important for developing more effective therapies for patients with advanced gastric, gastroesophageal junction, or esophageal adenocarcinoma.

The trial will involve the use of two main treatments. The first is [18F]FAPI-74, a solution for injection that helps in imaging cancer cells. The second is Telebrix Gastro, a solution taken orally or rectally, which is used as a bowel opacifier to improve imaging results. The study will compare the effectiveness of these treatments in detecting cancer in newly diagnosed patients who have not yet received treatment. The goal is to determine if the new imaging method can provide better information about the cancer, which could help in planning the best treatment approach.

Participants in the study will undergo imaging tests using the new method, and the results will be compared to those from standard imaging techniques. The study will take place over a period of time, with the aim of gathering enough data to understand the benefits of the new imaging method. This research could potentially lead to improved ways of diagnosing and managing cancer, providing doctors with more accurate information to guide treatment decisions.

Participants in the study will receive the treatment as a solution for infusion, which means it will be given through a vein. The study will observe how the treatment affects the cancer and monitor any side effects. The trial will include regular check-ups and assessments to track the progress of the treatment. The study aims to understand how well the treatment works in shrinking the tumors and how safe it is for the patients.

The study will continue for several years, with the goal of gathering enough information to determine the treatment’s effectiveness and safety. This research is important for developing new ways to treat these challenging cancers and could potentially lead to new treatment options for patients in the future.

The trial will include patients with various types of advanced cancers, such as non-small cell lung cancer, renal cell carcinoma, urothelial bladder cancer, head and neck squamous cell cancer, breast cancer, gastric or gastroesophageal adenocarcinoma, epithelial ovarian cancer, cervical cancer, endometrial adenocarcinoma, prostate cancer, and soft tissue sarcoma. The study will be conducted in two phases. The first phase will focus on finding the right dose of JK06 by gradually increasing the amount given to patients. The second phase will involve giving the selected dose to more patients to further evaluate its effects.

Throughout the study, patients will receive the treatment every three weeks and will be monitored closely for any side effects or changes in their condition. The goal is to gather information that will help in developing JK06 as a potential treatment option for people with these types of advanced cancers. The study is expected to continue until 2028, with recruitment starting in 2024.

The study involves several medications used in chemotherapy. These include Docetaxel, Oxaliplatin, Calcium Folinate (also known as Leucovorin Calcium), and Fluorouracil (also known as 5-FU). These medications are given through an intravenous infusion, which means they are delivered directly into the bloodstream through a vein. Some patients in the study will receive these medications, while others may receive a placebo, which looks like the medication but does not contain any active ingredients.

Participants in the study will be randomly assigned to one of two groups. One group will receive the standard chemotherapy treatment after surgery, while the other group will have a reduced treatment plan, focusing more on monitoring and surveillance. The study will follow participants for several years to see how well they do in terms of survival and whether the cancer returns. The goal is to find out if less chemotherapy can be just as effective and safe as the standard treatment for patients with a low risk of cancer recurrence.

The study will involve participants receiving either AZD0901 or one of the standard treatments, which may include medications like Docetaxel, Irinotecan, Paclitaxel, Lonsurf (which contains trifluridine and tipiracil), or Cyramza (which contains ramucirumab). These treatments are typically administered as solutions for infusion, meaning they are given directly into the bloodstream through a vein, except for Lonsurf, which is taken as a tablet by mouth.

The purpose of the study is to determine if AZD0901 is more effective than the standard treatments in improving the health outcomes of participants. The trial will be conducted over several years, and participants will be monitored closely to assess the treatment’s impact on their cancer and overall health. Some participants may receive a placebo, which is a substance with no active medication, to help compare the effects of the treatments being studied. The study will help researchers understand how well AZD0901 works and its safety profile compared to existing cancer therapies.

Participants in the study will receive the treatment through an intravenous infusion, which means the medication is given directly into a vein. The study will also include other medications such as Leucovorin, Taxotere (docetaxel), medoxa (oxaliplatin), and 5-FU (fluorouracil), which are commonly used in chemotherapy. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects of the treatment. The purpose of the study is to assess how effective this treatment is in avoiding surgery and reducing the risk of complications, as well as to monitor the response of the cancer to the treatment.

The study will take place over several months, with regular check-ups and evaluations to monitor the participants’ health and the progress of the treatment. The main focus will be on the rate of complete response, meaning the cancer is no longer detectable, at the time of endoscopic re-evaluation, which is a procedure that uses a camera to look inside the esophagus. The study will also look at the long-term effects of the treatment, including the rate of response after one, two, and three years, as well as any side effects or adverse events that may occur. Participants will be closely monitored to ensure their safety and well-being throughout the study.

Participants in the study will take metformin orally, which means they will swallow the tablets. The study will involve taking metformin for a short period of two weeks. During this time, researchers will collect information by comparing tumor samples taken before and after the treatment. This will help them understand if there are any changes in the immune cells within the tumor, specifically looking at certain types of cells called macrophages and T cells. These cells play a role in the body’s defense against cancer.

The study will also monitor other aspects, such as any side effects experienced by participants and how the cancer responds to treatment over time. The goal is to see if metformin can make the cancer treatment more effective and improve outcomes for patients with oesophageal adenocarcinoma. This research could provide valuable insights into new ways to enhance cancer treatment by using existing medications like metformin.

The purpose of this research is to determine if using zanidatamab with chemotherapy, either alone or together with tislelizumab, works better than the current standard treatment of trastuzumab with chemotherapy. Zanidatamab and tislelizumab are new medications that work by helping the body’s immune system fight cancer cells. During treatment, patients may also receive loperamide, a medication that helps control diarrhea which can occur as a side effect of treatment.

Participants in this study will be randomly assigned to receive either the new treatment combination or the standard treatment. The medications will be given through an intravenous infusion (delivered directly into a vein), while some medications will be taken by mouth. The study treatment may continue for up to 756 days, depending on how well it works and how well it is tolerated by patients.

The purpose of the study is to see if adding trastuzumab and pertuzumab can help improve the overall survival of patients with this type of cancer. Participants in the study will receive either the standard treatment or the standard treatment plus the two additional medications. Some participants may receive a placebo instead of the additional medications. The study will follow participants over a period of time to monitor their health and the effectiveness of the treatment.

Throughout the study, researchers will look at various outcomes, including how long patients live, how well the cancer responds to treatment, and the quality of life of the participants. The study will also assess the safety of the treatment by monitoring any side effects or complications that may occur. The goal is to gather information that could lead to better treatment options for people with HER2-positive esophageal adenocarcinoma in the future.

Participants in the study will be randomly assigned to one of the two treatment groups. The treatments will be given through an intravenous infusion, which means the medication is delivered directly into the bloodstream through a vein. The study will last for a period of up to 12 months, during which time patients will receive regular treatments and be monitored for any changes in their condition. The study will also include a group of patients who will receive a placebo, which is a substance with no active medication, to compare the effects of the treatments.

The trial aims to provide valuable information on the effectiveness of these treatment combinations in managing advanced stomach cancer. By comparing the two groups, researchers hope to determine which combination offers better outcomes in terms of survival and response to treatment. This study is important for developing new strategies to treat patients with this type of cancer, especially those who have not had success with previous therapies.

The purpose of this research is to determine if adding radiation therapy to chemotherapy before surgery works better than using chemotherapy alone before and after surgery for treating this type of cancer. The study compares these two different approaches to find out which one is more effective at preventing the cancer from returning.

Patients who participate in the study will receive treatment for approximately 33 weeks. During this time, they will receive either chemotherapy alone or chemotherapy combined with radiation therapy, followed by surgery to remove the cancer. After surgery, doctors will monitor the patients’ progress to see how well the treatment worked and check for any side effects.

The purpose of this study is to see if the combination of Durvalumab and FLOT chemotherapy, followed by additional Durvalumab treatment, can improve outcomes for patients with resectable gastric or gastroesophageal junction cancer. “Resectable” means that the cancer can be surgically removed. The study will be conducted in phases, starting with treatment before surgery (neoadjuvant) and continuing after surgery (adjuvant). Participants will be randomly assigned to receive either the active treatment or a placebo, and neither the participants nor the researchers will know who is receiving which treatment until the study is completed. This is known as a double-blind study.

The study will last for a period of up to 18 months, during which participants will receive the treatments and be monitored for their health and response to the treatment. The main goal is to assess event-free survival, which means the length of time participants live without the cancer getting worse or coming back. Secondary goals include overall survival and the rate of complete response to the treatment. This study aims to provide valuable information on the effectiveness of Durvalumab in combination with FLOT chemotherapy for treating gastric and gastroesophageal junction cancers.

The trial will involve several medications, including capecitabine, calcium folinate, fluorouracil, oxaliplatin, and new investigational drugs such as Rilvegostomig (also known as AZD2936), volrustomig (MEDI5752), AZD7789, and AZD0901. These medications will be administered in different combinations to evaluate their impact on the cancer. Some of these drugs are given as tablets, while others are administered through an infusion, which means they are delivered directly into the bloodstream through a vein.

The purpose of the study is to assess how well these new drug combinations work in treating the cancer and to monitor their safety. Participants will receive treatment over a period of up to 24 months. The study will track how the cancer responds to the treatment and whether the participants remain free from disease progression for at least six months. The trial will also monitor any side effects and how the body processes the drugs. Some participants may receive a placebo as part of the study. The trial aims to provide valuable information that could lead to better treatment options for this type of cancer in the future.

Participants in the study will receive either tocilizumab or a placebo, in addition to their regular cancer treatment. The study will monitor how well the cancer responds to the treatment by looking at changes in the tumor tissue. This will help researchers understand if tocilizumab can make the standard treatment more effective. The study will also look at other factors, such as the rate of successful tumor removal through surgery and the overall survival of participants.

Throughout the study, researchers will collect information on the safety of tocilizumab, including any side effects or complications that may arise. They will also measure certain proteins and genes in the blood and tumor tissue to understand how tocilizumab works in the body. The study aims to provide valuable insights into whether tocilizumab can be a beneficial addition to the treatment of esophageal adenocarcinoma.

The purpose of the study is to compare the overall survival of participants receiving pembrolizumab with chemotherapy to those receiving a placebo with chemotherapy. Participants in the study have HER2-negative cancer, which means their cancer cells do not have a protein called HER2 on their surface. The study is designed to be double-blind, meaning neither the participants nor the researchers know who is receiving the pembrolizumab or the placebo. This helps ensure the results are unbiased.

Participants will receive treatment through intravenous infusion, which means the medication is given directly into a vein, and some medications may be taken orally. The study will follow participants over a period to monitor their response to the treatment and any side effects they may experience. The goal is to determine if pembrolizumab, when combined with chemotherapy, can improve survival rates for people with advanced gastric or gastroesophageal junction adenocarcinoma.

The purpose of this study is to understand the safety and tolerability of JK08, as well as to determine the best dose for patients. The study will begin with a phase where different doses of JK08 are tested to find the maximum dose that patients can tolerate. After this, the study will expand to include more patients to further evaluate the optimal dose. Patients participating in the study will receive JK08 through subcutaneous use, which means it is injected under the skin. Some patients may also receive Keytruda through infusion, which is a method of delivering medication directly into the bloodstream, or Lenvima in the form of hard capsules taken orally.

This trial is open to patients with various types of advanced cancers, including non-small cell lung cancer, small cell lung cancer, melanoma, renal cell carcinoma, urothelial cancer, head and neck squamous cell cancer, breast cancer, gastric cancer, esophageal cancer, pancreatic cancer, liver cancer, colorectal cancer, ovarian cancer, cervical cancer, endometrial cancer, and thyroid cancer. The study aims to provide new insights into the treatment of these cancers and potentially offer new therapeutic options for patients who have limited treatment choices.

The purpose of the study is to determine how well zolbetuximab works in treating this type of cancer. Participants in the study will receive treatments through an intravenous infusion, which means the medication is given directly into a vein. The study will monitor the response of the cancer to the treatment, as well as the safety and tolerability of the drugs. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects of the actual drugs being tested.

The study will take place over a period of time, during which participants will receive regular treatments and undergo assessments to track their progress. The goal is to gather information on how effective zolbetuximab is, both on its own and in combination with other treatments, in improving outcomes for patients with advanced stomach or gastroesophageal junction cancer. The study will also look at the side effects and overall impact on the quality of life for those participating.

The purpose of this study is to evaluate how well this combination of medications works in treating the cancer before and after surgery. Participants in the study will receive the treatment over a period of time, and their response to the treatment will be monitored. The study aims to determine the rate of response to the treatment according to specific criteria, as well as to assess the safety and potential side effects of the treatment.

Throughout the study, participants will be closely monitored for any changes in their condition, and the effectiveness of the treatment will be evaluated at various points. The study will also look at the rate of successful surgical removal of the cancer and track the participants’ health over several years to understand the long-term effects of the treatment. This research is part of a larger effort to improve treatment options for patients with these types of cancer.

Participants in the study will receive either MK-2870 or a treatment selected by their physician. The study will also involve other medications such as trifluridine and tipiracil, which are combined in one treatment, as well as paclitaxel, docetaxel, and irinotecan hydrochloride. These medications are commonly used in cancer treatment and will be administered through intravenous infusion, which means they are given directly into a vein. Some participants may also receive medications like H2-receptor antagonists, glucocorticoids, antihistamines, and pain relievers like paracetamol and codeine phosphate to help manage symptoms or side effects.

The study will take place over a period of time, with regular check-ups and assessments to monitor the participants’ health and the effectiveness of the treatment. The main goal is to determine which treatment helps patients live longer and to understand any side effects that may occur. Participants will be closely monitored by healthcare professionals throughout the study to ensure their safety and well-being.

The purpose of the study is to evaluate how well these treatments work in preventing the cancer from coming back or spreading, and to assess the overall survival of patients. The study will also look at the safety and side effects of the treatments. Participants will receive the treatments before and after surgery to remove the cancer. The study will follow participants over a period of time to monitor their health and the effectiveness of the treatments.

Throughout the study, participants will receive the treatments through intravenous infusion, which means the medication is given directly into a vein, or orally, which means taking the medication by mouth. The study aims to provide valuable information on the best treatment options for patients with gastric and GEJ adenocarcinoma, helping to improve future care and outcomes for individuals with these types of cancer.

The purpose of this study is to find a suitable dose of zongertinib when used in combination with either trastuzumab deruxtecan or trastuzumab emtansine, and to see if these combinations can help people with these types of cancer. The study is divided into two main parts. The first part, called Phase Ib, involves gradually increasing the dose of zongertinib to determine the highest dose that can be given safely. The second part, Phase II, aims to find out how effective the treatment is at shrinking tumors or stopping them from growing. Participants will receive the study medications and be monitored for any side effects and how well the treatment is working.

Throughout the study, participants will have regular check-ups and tests to assess their health and the progress of their cancer. The study will help researchers understand the best way to use these medications together and whether they can provide a new treatment option for people with these advanced cancers. The study is expected to continue until 2028, with recruitment starting in 2024.

Participants in the study will receive Disitamab Vedotin, which is given as an infusion, meaning it is administered directly into the bloodstream through a vein. Tucatinib is taken as a tablet by mouth. The study will explore how these treatments work in different groups of patients, including those with HER2-low and HER2-positive breast cancer, as well as those with HER2-low gastric cancer. HER2 is a protein that can affect the growth of cancer cells, and the study will look at how the treatments perform in patients with varying levels of this protein.

Throughout the study, researchers will monitor participants for any side effects and will assess how well the cancer responds to the treatment. The study aims to gather information on the safety of the treatments and their ability to control or reduce the cancer. This information will help determine the potential benefits of using Disitamab Vedotin and Tucatinib for these types of cancer.

The purpose of the study is to determine if these treatments can help patients live longer without their cancer getting worse. Participants in the trial will receive either the FOLFOX treatment or the TFOX treatment. Some participants may receive a placebo. The study will last for a period of up to 24 months, during which time the effects of the treatments will be monitored and compared.

By participating in this trial, researchers hope to gather important information about the potential benefits of adding anhydrous docetaxel to the standard FOLFOX treatment for patients with locally advanced or metastatic oesophago-gastric adenocarcinoma. The ultimate goal is to improve the quality of life and survival rates for individuals affected by this type of cancer.

The purpose of this study is to evaluate how effective sacituzumab govitecan is for patients with metastatic esophagogastric adenocarcinoma. Participants in the study will receive the medication through an intravenous infusion, which means it will be administered directly into a vein. The study will follow a single-arm design, meaning all participants will receive the same treatment without a comparison group. Some participants may receive a placebo, which is a substance with no active medication, to help researchers understand the effects of the treatment.

Throughout the study, researchers will monitor participants to assess their response to the treatment. This includes looking at the overall response rate, which measures how well the cancer responds to the medication. The study aims to provide valuable information about the potential benefits of sacituzumab govitecan for treating this type of cancer. Participants will be closely observed by medical professionals to ensure their safety and to gather important data about the treatment’s effectiveness.

The purpose of the study is to see if taking budesonide for eight weeks can help prevent the formation of esophageal strictures in adults who have undergone the endoscopic procedure. Participants in the study will be randomly assigned to receive either a low dose or a high dose of budesonide, or a placebo. The study is designed to be double-blind, meaning neither the participants nor the doctors will know who is receiving the actual medication and who is receiving the placebo. This helps ensure that the results are not influenced by expectations about the treatment.

Throughout the study, participants will take the medication or placebo for a total of eight weeks. The main goal is to determine how many participants remain free of esophageal strictures by the end of the study period. Additionally, the study will track the number of times participants need a procedure called endoscopic dilation, which is used to widen the esophagus if strictures do occur. The results will help determine if budesonide is an effective treatment for preventing esophageal strictures after endoscopic submucosal dissection.